Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment

MLA

Sabesan Yoganathan, et al. “Tyrosine Kinase Inhibitor Conjugated Quantum Dots for Non-Small Cell Lung Cancer (NSCLC) Treatment.” European Journal of Pharmaceutical Sciences, vol. 133, May 2019, pp. 145–59. EBSCOhost, https://doi.org/10.1016/j.ejps.2019.03.026.

APA

Sabesan Yoganathan, Nishant S. Kulkarni, Jeanette C. Perron, Aaron Muth, Leonard Barasa, Vineela Parvathaneni, Vivek Gupta, & Snehal K. Shukla. (2019). Tyrosine kinase inhibitor conjugated quantum dots for non-small cell lung cancer (NSCLC) treatment. European Journal of Pharmaceutical Sciences, 133, 145–159. https://doi.org/10.1016/j.ejps.2019.03.026

Chicago

Sabesan Yoganathan, Nishant S. Kulkarni, Jeanette C. Perron, Aaron Muth, Leonard Barasa, Vineela Parvathaneni, Vivek Gupta, and Snehal K. Shukla. 2019. “Tyrosine Kinase Inhibitor Conjugated Quantum Dots for Non-Small Cell Lung Cancer (NSCLC) Treatment.” European Journal of Pharmaceutical Sciences 133 (May): 145–59. doi:10.1016/j.ejps.2019.03.026.